Introduction
Implementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a first episode of psychosis (FEP) is a complex and crucial task, with relevant impact in illness outcome (Crespo-Facorro et al., 2016) . Antipsychotics have demonstrated over the last four decades that they work both to treat acute psychotic episodes and to reduce relapse rates over the short to medium term (Correll et al., 2018) . Prevention of recurrent episodes is likely to be critical to prevent disease progression (Emsley et al., 2013; Pelayo-Terán et al., 2017) .
Relapses involve an increased risk for a poorer and delayed response in the subsequent episode with higher treatment doses, potential side-effects emergence and, longer duration of active psychosis determining neurotoxicity (Pelayo-Terán et al., 2018; Takeuchi et al., 2018) . Nonadherence to medication seems to represent the highest risk for relapse after a FEP. Lack of efficacy, poor tolerability and acceptability are the other main causes that increase the risk for discontinuation during early phases after a FEP.
Hence, higher treatment discontinuation rates are linked to higher relapse rates and a worsened prognosis . That is why FEP first-line antipsychotic choice is so critical. A recent meta-analysis focused on long term patients with schizophrenia suggested that, although there are some significant differences in effectiveness, efficacy and tolerability among second generation antipsychotics (SGAs) in the long-term treatment of schizophrenia, due to the limited number of head-to-head clinical trials available so far, the comparative effectiveness of some SGAs is unclear (Kishimoto et al., 2019) . So that, knowledge about the comparative clinical characteristics of antipsychotics in the long-term treatment (in which the magnitude of benefits and risks of medications may be different from acute phase treatment) of schizophrenia is important albeit insufficient so far (Correll and Hert, 2013) . Thus, with this pool analysis, comparing head-to-head 6 antipsychotics widely used in routine clinical settings, we aim to add detailed information on effectiveness, efficacy and tolerability outcomes to contribute to further guide the evidence-based long-term treatment of patients with schizophrenia (Crespo-Facorro et al., 2012; Gómez-Revuelta et al., 2018) . This may lead to identify predictors of beneficial outcomes with specific antipsychotics which would further enhance the ability to personalize treatments.
We hypothesize that differences regarding to efficacy, tolerability and adherence would result in differential effectiveness to lead such a critical election as first antipsychotic choice may be for the outcome of FEP patients.
Experimental procedures

Study setting
Data for the present investigation were obtained from an ongoing 3-year longitudinal intervention program of first-episode psychosis called PAFIP (Programa de Atención a las Fases Iniciales de Psicosis) conducted at the outpatient clinic and the inpatient unit of the University Hospital Marqués de Valdecilla, Spain (Pelayo-Terán et al., 2008) .
Conforming to international standards for research ethics, this program was approved by the local institutional review board. Patients meeting inclusion criteria and their families provided written informed consent prior to their inclusion to the program.
Subjects
From February 2001 to January 2011, all referrals to PAFIP were screened for patients who met the following criteria: (1) 15-60 years; (2) living in the catchment area; (3) experiencing their first episode of psychosis; (4) no prior treatment with antipsychotic medication or, if previously treated, a total lifetime of adequate antipsychotic treatment of less than 6 weeks; (5) DSM-IV criteria for brief psychotic disorder, schizophreniform disorder, schizophrenia, psychotic disorder not otherwise specified or schizoaffective disorder. Patients were excluded for any of the following reasons: (1) meeting DSM-IV criteria for drug dependence, (2) meeting DSM-IV criteria for mental retardation, (3) having a history of neurological disease or head injury. The diagnoses were confirmed using the Structured Clinical Interview for DSM-IV (SCID-I) (First et al., 2002) carried out by an experienced psychiatrist, 6 months on from the baseline visit. Our operational definition for a "first episode of psychosis" included individuals with a non-affective psychosis (meeting the inclusion criteria defined above) regardless of the duration of untreated psychosis.
Study design
Patients included in this study were assigned in two different albeit consecutive phases of the PAFIP (2001-2004 and 2005-2011) We used a simple randomization procedure. An automated randomization list was drawn up. At study intake, all patients but eleven (2.92%) were antipsychotic naïve (mean duration of prior treatment = 2.75-weeks; SD=1.8; range=0.4-4.0). Before starting on the assigned drug, these subjects underwent a 2-4-day washout period. Mean antipsychotic Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyaa004/5715030 by guest on 06 February 2020 A c c e p t e d M a n u s c r i p t 8 doses expressed as chlorpromazine equivalents (CPZeq; mg/day) (Woods, 2003) were as follow: olanzapine 5-20 mg/day (100-400 CPZeq), risperidone 3-6 mg/day (150-300 CPZeq), haloperidol 3-9 mg/day (150-450 CPZeq), quetiapine 100-600 mg/day (133.33-800 CPZeq), ziprasidone 40-160 mg/day (66.67-266.67 CPZeq), and aripiprazole 5-30 mg/day (66, . Rapid titration schedule (5 days), until optimal dose was reached, was used as a rule unless severe side effects occurred.
At the treating psychiatrist´s discretion, the dose and type of antipsychotic medication could be changed based on clinical efficacy and the profile of side effects during the follow-up period. Anticholinergic medication, lormetazepam and clonazepam, were permitted for clinical reasons. No anticholinergic agents were administered prophylactically. Antidepressants and mood stabilizers were permitted if clinically needed. The severity scale of the Clinical Global Impression (CGI) scale (Guy, 1976) , the Brief Psychiatric Rating Scale (BPRS) (expanded version of 24 items) (Overall and Gorham, 1962) , the Scale for the Assessment of Positive symptoms (SAPS) (Andreasen, 1984) , the Scale for the Assessment of Negative symptoms (SANS) (Andreasen, 1989) , the Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1993) (Lingjaerde et al., 1987) , the Simpson-Angus Rating Scale (SARS) (Simpson and Angus, 1970) and the Barnes Akathisia Scale (BAS) (Barnes, 1989) were used to assess side effects. Clinical assessments and measurements were completed at baseline, at 3-week, at 6-week, 3-month, 6-month, 12-month, 18-month, 24-month, 30- month and 36-month. All patients included in the analysis had at least the baseline and 3-year assessments and they were considered for drop-out in those cases in which they did not attend to two consecutive check-point assessments. The same trained psychiatrist Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyaa004/5715030 by guest on 06 February 2020 A c c e p t e d M a n u s c r i p t 9 (BC-F) completed all clinical assessments.
Outcome measures
Primary outcome measures: effectiveness
The main outcome of effectiveness was the all-cause treatment discontinuation rate, which is the percentage of all-cause discontinuation of the initially assigned treatment (patients who completed the 3-year follow-up assessment and their initial antipsychotic treatment was switched during follow-up) and the mean time to all-cause medication discontinuation. Four reasons for the discontinuation were recorded: (1) non or insufficient efficacy; (2) significant side-effects; (3) non-adherence and (4) other causes.
Insufficient efficacy was established at the treating physician's judgment only after at least 3 weeks of treatment. Adherence to antipsychotic drugs was assessed by the information obtained from patients, close relatives and by the staff (nurse, social worker and psychiatrists) involved in the follow-up. According to previous definition (Gómez-Revuelta et al., 2018) patients were consensually dichotomized into having a good (defined as patients regularly taking at least 90% of prescribed medication) and a poor adherence (medium or poor compliance). If more than one reason for discontinuation was present, the most important reason according to the above ranking was selected.
Secondary outcome measures: efficacy and safety
The efficacy outcomes were the mean change from baseline to 3-year in BPRS, SAPS and SANS total scores. Additional analyses included changes from baseline to 3-year in CGI, YMRS and CDSS total scores. Patients were defined as responders to the optimum dose of antipsychotic if they had a ≥50 % reduction of BPRS total-score and a CGI severity-score ≤4 after 6-months since the beginning of the treatment. Side-effects were Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyaa004/5715030 by guest on 06 February 2020 A c c e p t e d M a n u s c r i p t 10 evaluated using the UKU side effects rating scale. Only side-effects rated as moderate or severe and with a possible causal relationship to medication were recorded. Treatmentemergent akathisia and extrapyramidal symptoms were assessed using BAS and SARS scales.
Statistical analyses
All data were tested for normality (using Kolmogorov-Smirnov test) and equality of variances (using Levene test). To ensure group comparability, baseline sociodemographic and clinical characteristics were tested by 1-way analyses of variance (ANOVA) or Kruskal-Wallis tests for continuous variables or by Chi-squared tests for qualitative variables.
Kaplan-Meier survival curves and log-rank tests were used to assess time to all-cause medication discontinuation. Concerning these two analyses, patients were followed up from the inclusion in the study until discontinuation of the initial treatment or censoring.
Survival time could be censored by the end of the observation period or by lost to followup.
For efficacy and safety measures, we performed both intention-to-treat analyses and perprotocol analyses. Differences between groups in the degree of change in clinical scores from baseline were evaluated with analysis of covariance after baseline scores were controlled. Finally, comparisons of the discontinuation rates and the prevalence of side effects as well as the use of concomitant treatment between the six antipsychotics were carried out, performing Chi-Square tests with Bonferroni correction for multiple comparisons when necessary. 
Results
Out of 406 individuals who were initially randomized to treatments, 30 were finally removed from data set after verifying they did not fully meet inclusion criteria or remove proper written consent during the first week. Thus, the final sample consisted of 376 subjects who were randomly assigned to six different antipsychotic treatments: 55 patients were randomly assigned to the olanzapine group, 63 to the risperidone group, 56 to the haloperidol group, 78 patients to the aripiprazole group, 62 were assigned to the quetiapine group and 62 to the ziprasidone group ( Figure 1 ). The overall dropout rate at 3-year was small (N=78; 20.74%). 46 patients dropped-out follow-up prior to treatment discontinuation and were censored for the survival analysis (5-haloperidol, 9olanzapine, 10-risperidone, 9-aripiprazole, 8-quetiapine and 5-ziprasidone). Our study gave the option to patients who were stable (symptom free for at least 12-month) and functionally recovered (at least 6-month under sustained recovery) to discontinue use of antipsychotic treatment while continuing to be followed up by study clinicians (Mayoral-van Son et al., 2017) . Seventeen patients entered this antipsychotic discontinuation program and were carefully monitored during the following 18 months after discontinuation. 16 out of these 17 patients completed the 3-year assessment but, they were censored for the primary outcome analysis. 5 patients committed suicide during the 3-year follow-up (1olanzapine, 1 aripiprazole, 1 ziprasidone and 2 quetiapine) and there was 1 sudden death (aripiprazole; heart attack).
All but 11 individuals in the study were white Caucasian (no significant differences were found between treatment groups after Bonferroni correction). Instead, we found Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyaa004/5715030 by guest on 06 February 2020 A c c e p t e d M a n u s c r i p t 12 significant differences between treatment groups concerning some demographic variables (Living with parents, single status, age at admission, age at FEP onset and duration of illness (DUI)) which were adjusted by Bonferroni correction later.
Demographic and clinical characteristics of patients are shown in Table 1 .
Primary outcome measures:
Treatment discontinuation rate and time to discontinuation An impressive 79.25 % of the initial sample completed follow-up. Overall treatment discontinuation rate (the cumulative percentage of discontinuation considering the six arms of the study) also reached 79.25% by 3-year, which is in line with other medium and long-term (52 weeks or more) follow-up studies (Lieberman et al., 2005; Kahn et al., 2008a) .It differed significantly between treatment groups (χ 2 =79.860; p=0.000) ( Table   2 ). Patients on quetiapine showed a higher (95.16 %) treatment discontinuation rate than olanzapine (69.09%), risperidone (71.43%), aripiprazole (73.08 %), ziprasidone (79.03 %) or haloperidol (89.28%) individuals. The mean time (days) until discontinuation was 855 days for olanzapine, 786 days for risperidone, 452 days for aripiprazole, 295 days for haloperidol, 251 days for ziprasidone and 60 days for quetiapine. There was a significant difference between groups (Log Rank=90.240; p=0.000) (see Fig. 2 ). Log-Rank pairwise comparisons showed no statistical differences between olanzapine, risperidone and aripiprazole. However, results differed significantly favoring any antipsychotic when compared to quetiapine: aripiprazole (χ2=28.95; p<0.001), ziprasidone (χ2=14.29; p<0.001), olanzapine (χ2=45.56; p=0.156), haloperidol (χ2=18.84; p<0.001) and risperidone (χ2=46.52; p<0.001). Results also highlighted higher effectiveness of risperidone (χ2=9.44; p=0.002) and aripiprazole (χ2=7.657; p=0.022) over haloperidol.
Olanzapine also took significant advantage over haloperidol (χ2=11.23; p=0.001) and ziprasidone (χ2=8.81; p=0.003). We only found a trend towards non-discontinuation Downloaded from https://academic.oup.com/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyaa004/5715030 by guest on 06 February 2020 A c c e p t e d M a n u s c r i p t 13 favoring aripiprazole and risperidone over ziprasidone and no differences were found between ziprasidone and haloperidol. Non or insufficient efficacy in the group of quetiapine was the main reason for discontinuation rate differences (χ2=87.43; p=0.000).
Patients under quetiapine treatment were significantly more likely to discontinue due to non or insufficient efficacy compared to aripiprazole (χ2=32.15; p=0.000), ziprasidone (χ2=19.35; p=0.000), olanzapine (χ2=39.91; p=0.000), risperidone (χ2=41.17; p=0.000), or haloperidol patients (χ2=27.83; p=0.000). No significant differences were found between the remaining treatment groups. Mean (SD) doses (adjusted by chlorpromazine equivalents) prior to discontinuation due to non or insufficient efficacy were:
aripiprazole-520 CPZeq (SD= 131.7), ziprasidone-386.5 CPZeq (SD= 149.5), haloperidol-351.8 CPZeq (SD= 164.9), olanzapine-510 CPZeq (SD= 292.4), risperidone-550 CPZeq (SD= 229.1) and quetiapine-586.2 CPZeq (SD= 251.1). Analysis of treatment discontinuation due to side effects revealed significant differences between groups (quetiapine 12.9%, ziprasidone 37.1 %, risperidone 31.7%, olanzapine 14.5%, haloperidol 31.1% and aripiprazole 12.82 %; χ2=19.800; p =0.001). Patients on ziprasidone discontinued treatment due to side effects significantly more frequently than those on aripiprazole (χ² =11.490; p= 0.001), olanzapine (χ² = 12.400; p=0.000) or quetiapine (χ² = 9.677; p=0.006). We did not find significant differences in the direct comparisons between the remaining groups. Finally, there was a remarkable difference in terms of treatment adherence as individuals in the risperidone group showed better adherence than those individuals in the aripiprazole ( 
Secondary outcome measures:
Clinical efficacy ANCOVA analyses showed multiple differences (Table 3) in the changes of the total scores of the clinical scales between treatments after controlling by baseline measurements except for the SANS score (p=0.265) and the negative dimension score (p=0.314). Thereby, significant differences on clinical scales showed that CGI improvement: significantly larger for aripiprazole vs haloperidol and ziprasidone vs haloperidol, and olanzapine; SAPS score: olanzapine improvement significantly lower when compared to aripiprazole and ziprasidone; Positive dimension: aripiprazole and ziprasidone scores were significantly lower than those proceeding from haloperidol and olanzapine patients; Disorganized dimension: patients on aripiprazole, quetiapine and ziprasidone got significant larger improvements than olanzapine patients; CDSS score: ziprasidone and quetiapine patients got significant improvements in depressive symptoms compared to haloperidol patients; YMRS score: significant improvement for aripiprazole when compared to olanzapine. Per protocol analyses solely unveiled significant differences concerning CGI (p=0.008) and YMRS (p=0.001) baseline scores. Bonferroni post-hoc analyses showed significant baseline higher scores for aripiprazole compared to olanzapine and risperidone for both clinical scales (data available upon request). Intention-to-treat analyses of moderate and severe side effects that were frequent (at least in 5% of patients in any of the treatment groups) are displayed in Table 4 . Significant differences between treatments were found in the categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, and amenorrhea.
Safety
Adverse events
After adjustment by Bonferroni correction, aripiprazole showed to cause less increased sleep duration than quetiapine (p=0.015) and ziprasidone (p=0.05) and risperidone was also less likely to do so than olanzapine, quetiapine, haloperidol and ziprasidone (all p´s< 0.05). Quetiapine was associated to increased somnolence compared to aripiprazole (p=0.034) but amenorrhea was significantly less likely to emerge on this group compared to haloperidol (p=0.037) and risperidone (p=0.022). Risperidone produced an increased frequency of ejaculatory dysfunction than aripiprazole (p=0.034). Instead, aripiprazole patients were more likely to suffer akinesia when compared to olanzapine (p=0.004) and ziprasidone (p=0.033). Finally, olanzapine caused a significantly higher weight gain rate than ziprasidone (p=0.001). Per-protocol analysis showed rather similar results (data available on supplementary material). In this sense, there were only three side-effect categories that showed statistically significant differences (weight gain, sialorrhea and ejaculatory dysfunction). None of them resulted in statistical significance after post-hoc analyses.
Extrapyramidal symptoms
Significant differences in the SARS total score changes at 3 year between treatments were found (F =13.441; p =0.020). The percentage of patients with treatment-emergent EPS was statistically different between treatments (aripiprazole=23.8 %, ziprasidone= 23.5 %, quetiapine 20 %, risperidone 40%, olanzapine 30%, haloperidol 48.8%; χ2=13.441; p =0.020). Haloperidol supplied a significant burden of extrapyramidal side effects compared to aripiprazole, quetiapine and ziprasidone (all p´s<0.05) and, so did risperidone after comparison to quetiapine (p=0.043). There was not a significant difference between treatments in the severity of akathisia (BAS total score) (F =0.939; p =0.456). Although the difference did not reach a significant level, a higher number of individuals in the aripiprazole (22.6 %), haloperidol (27.7%) and ziprasidone groups (32.7 %) experienced treatment emergent akathisia compared to the other groups (quetiapine 17.8 %, olanzapine 4.7% and risperidone 17.8%). These differences were significant for the UKU scale akathisia item (χ² =11.932; p = 0.036) but, after Bonferroni correction, only the differences between ziprasidone and olanzapine groups remained significant (p=0.001). Per protocol analyses showed no statistically significant differences.
Concomitant medication use
Significant differences were found between treatment groups regarding the use of benzodiazepines (χ² = 21.52, p = 0.001), hypnotics (χ² = 47.76, p= 0.004), and anticholinergics (χ² = 43.76, p= 0.004). After adjustment by Bonferroni correction, we found that the benzodiazepine use in the aripiprazole group was significantly higher than in the quetiapine, haloperidol, olanzapine and risperidone groups (all p´s<0.05); similarly, aripiprazole, quetiapine and ziprasidone patients needed hypnotics more frequently than in olanzapine, risperidone and haloperidol patients (all p´s <0.05 except for the comparison between quetiapine and haloperidol). Almost half of the sample required treatment with anticholinergics at any time of the follow-up. Olanzapine (27.27%) stood out for being the treatment group which needed least frequently this sort of treatment (Table 5 ). Our aim with this research was to supply information from our experience to guide the choice of the first-line treatment for a FEP. Results show remarkable effectiveness, efficacy and safety differences between the six antipsychotics included in the study. We distinguished two treatment groups according to their effectiveness performance, multiple tolerability profiles and different efficacy measures.
Discussion
Given that almost all the SGAs have reduced risk of EPS and tardive dyskinesia than FGAs, and not all lead to important weight gain, and many are now available both in oral and long-acting intramuscular forms, treatment with a SGA would be the first choice in most cases (Smith et al., 2019) .
Primary outcome measures: Treatment discontinuation rate and mean time to discontinuation Different patterns for discontinuation emerged at different phases during follow-up. This circumstance may determine different intensity interventions focused on efficacy, compliance and tolerability adapted to each specific phase of the follow-up: Over half of the patients who discontinued treatment, did so during the first year after the outbreak (52.68% by the end of 1-year) of whom 40.71% discontinued treatment due to lack of efficacy. Compelling this information, it is remarkable that mean-time until all-cause discontinuation occurred extended for more than two years in the olanzapine and risperidone groups and slightly for more than one year in the aripiprazole group. Instead whilst non-adherence (30.54%) was the main cause for discontinuation between 1-year and 3-year follow-up. Concerning the all-cause discontinuation rate and the mean time to discontinuation variables, we may split the antipsychotic treatments used for this research into two different groups according to their performance on preventing patients from discontinuation due to any cause: a leading group composed by olanzapine, risperidone and aripiprazole and an underperformer group including ziprasidone, quetiapine and haloperidol. So that, olanzapine, risperidone and aripiprazole proved to be significantly superior to quetiapine and haloperidol. Meanwhile, though ziprasidone was superior to quetiapine and haloperidol as well, it was significantly defeated by olanzapine and both aripiprazole and risperidone showed a trend towards superiority compared to ziprasidone.
There were no significant differences between olanzapine, risperidone and aripiprazole concerning any-cause discontinuation risk and mean time to discontinuation, though olanzapine performed slightly better, especially in terms of mean time to discontinuation which was almost 2-fold longer compared to aripiprazole. These data approaching aripiprazole effectiveness to that for other well-stablished effective antipsychotics had not been seen in other effectiveness studies . Higher risk of all-cause treatment discontinuation and shorter mean time to discontinuation in quetiapine patients had already been described during early phases of treatment (McEvoy et al., 2007) ; in our sample, 50% of patients on quetiapine discontinued treatment due to non or insufficient efficacy. Effectiveness studies using standard dosage ranges pointed out that quetiapine may be less effective than some other widely used SGAs (Tiihonen et al., 2017) and
FGAs (Vanasse et al., 2016) . Our results are consistent with the notion that most of the patients who start quetiapine, stop taking it within a few weeks (Asmal et al., 2013) .
Inadequate and transient dopamine−2 receptor occupancy has been proposed as a possible mechanism underlying quetiapine lack of efficacy. On the other hand, its weak dopamine antagonism allows low maximal occupancy values and relatively little variability in occupancy values, suggesting that high doses of this antipsychotic are not likely to exceed thresholds of more than 80% occupancy, indicative for D2-receptor-mediated side effects (Lako et al., 2013) . This supports the idea that higher doses may be tolerable and more efficient (Wang et al., 2017) . We did not find significant differences between groups concerning treatment dosage adjusted by chlorpromazine equivalents prior to discontinuation due to non or insufficient efficacy. Quetiapine group presented with the second higher relative dosage compared with the other groups. According to other reports (Tiihonen et al., 2017) it is difficult to discern whether the poorer performance of quetiapine is due to the product itself or to non-optimal dosage. Main reasons for discontinuation in the haloperidol group were non-adherence (28.57%) and side-effects (32.14%). Ziprasidone (37.1%) and risperidone (31.75%) patients were also more likely to discontinue treatment due to side-effects. Most of discontinuations due to side effects accrue during the 1-year follow-up. This difficulty arose during antipsychotic titration in these groups explaining why patients on ziprasidone and haloperidol tolerated lower relative doses than the remaining quartet. According to these results, EPS, sexual adverse events and somnolence (the most frequently reported secondary effects for discontinuation for risperidone, ziprasidone and haloperidol) seem to represent the worst tolerated side effects. On the next stage of follow-up (from 18-month on) we find an accumulation of treatment discontinuation due to nonadherence basically affecting aripiprazole (33.3%) and olanzapine (27.27%), for whom, this was the main reason for discontinuation. The increase in discontinuations due to non-adherence observed along the last year of follow-up in these groups might be explained by a natural decrease in the acceptability mediated by long-term exposure to treatment (Lieberman et al., 2005) . (Kishimoto et al., 2014; Jann and Penzak, 2018) , may be of interest in order to deal up with this preventable issue.
Improvements in educational and other prophylactical measures like the use of long
Secondary outcome measures
Efficacy
Our first-episode patients showed a decrease in total BPRS, SAPS, SANS and CGI scores during the 3-year follow-up. Previous studies using pair-wise meta-analytic (Leucht et al., 2009) comparisons have unfolded than SGAs like olanzapine, risperidone, amisulpride or clozapine are more efficacious than FGAs. Our study shows clear advantages for SGAs except for quetiapine when compared to haloperidol. More recent network meta-analyses have been able to discern differences even between SGAs with the formerly mentioned SGAs leading the rankings in terms of efficacy for positive symptoms. Curiously, in our long-term study, we find that after controlling for baseline and sociodemographic measures, efficacy was superior for aripiprazole and ziprasidone compared to olanzapine for positive symptoms and CGI improvement after 3-year. In previous short and mid-term studies involving the same sample, we did not find significant differences by 1-year (Crespo-facorro et al., 2011; Crespo-Facorro et al., 2014) . Clinical differences for positive symptoms seem to establish from that point on. Despite that apparent inferior efficacy, olanzapine offered the best performance regarding long-term discontinuation due to non or insufficient efficacy. It might be explained by the fact that most of non or insufficient efficacy discontinuations accrue during the first 6-month follow-up. No differences for remission or efficacy on positive symptoms were found during the 1-year follow-up period in our sample but a decreasing trend towards inferiority for quetiapine. Optimal efficacy may critically impact for long-term discontinuation outcome during this early phase. Nevertheless, positive symptom long-term beneficious evolution, especially for aripiprazole, should be acknowledged when choosing first-line treatment after FEP. Regarding depressive symptoms, quetiapine is acknowledged as a first-line treatment even in monotherapy in affective-psychoses (Lindström et al., 2017) , but in several previous first-episode non affective psychoses studies, no significant differences between SGAs (including quetiapine) had been found in reducing depressive symptoms after mid-term follow-up (Kahn et al., 2008b) . No notable changes on negative symptoms were found with any of the six antipsychotics. Per protocol analysis did not show statistically significant differences along follow-up.
Side effects and concomitant medications
The differences in the percentage of patients with treatment-emergent parkinsonism may be of clinical interest. A higher percentage of extrapyramidal side effects was identified among patients treated with haloperidol and risperidone. As reported in previous studies, akathisia (Juncal-Ruiz et al., 2017) represented a challenge among aripiprazole and ziprasidone-treated individuals. These circumstances may partially explain that significantly more patients on aripiprazole and ziprasidone needed hypnotics, benzodiazepines and anticholinergics to relieve akathisia. In agreement with previous reports (Lee et al., 2011; Vázquez-Bourgon et al., 2018) , no significant differences were found in the frequency of body weight increase between treatments (except for the comparison between ziprasidone and olanzapine) but an uniform trend to weight increase was appreciated with all of them. Intention-to-treat analysis revealed that over 70% of the individuals on olanzapine showed a rapid body weight gain (Table 4 ). This should be regarded as a possible limitation for its first-line use as it contributes to a higher risk of metabolic issues (Smith et al., 2008) . Interestingly, discontinuation due to severe or intolerable side effects was the main cause for discontinuation in our study, though, remained relatively low (23.14 %). Anyway, it was significant in the case of ziprasidone and haloperidol as was their main cause of discontinuation. Sleepiness/sedation was the most prevalent reported secondary effect for discontinuation in the case of ziprasidone (N=8; 34.7%) and haloperidol despite low doses prior to discontinuation due to side effects (58.5mg (SD=34.3) and 1.8mg (SD=1.2), respectively). In the case of risperidone, we distinguished two patterns for discontinuation mediated by side effects; during the acute phase, most complaints focused on somnolence and EPS whilst during the second half of follow-up, discontinuation were due to sexual complaints and weight gain.
Olanzapine and quetiapine patients demonstrated lower secondary effects rates and the lowest discontinuation rates due to side-effects. However, they are linked with more incidence of metabolic impairment (Davy et al., 2016) and a higher risk for health events (Vanasse et al., 2016) . Thus, their use as first-line treatments should be considered cautiously. Per protocol analyses replicated the results for weight gain showing a trend towards significant weight gain in the olanzapine group consistent with extensive data available on research literature. Sialorrhea and ejaculatory dysfunction presented as well statistically significant results under per protocol analyses but no significant differences were identified between treatment groups.
Limitations and strengths
Several limitations should be considered when interpreting our results. First, as a practical clinical trial, patients and observers (BC-F) were not blinded to treatments in our study.
The fact that the observers knew the medications prescribed, may have involuntarily biased the outcomes. As a non-industry-funded study, the risk for systematic biased measuring study outcomes favoring any of the treatments is limited. Second, the mean doses of quetiapine used could be understood as somewhat low to treat first-episode Optimal doses of antipsychotics within licensed range were chosen based on clinical efficacy and the presence of side-effects and were adjusted according to the clinical situation of each patient. It is important to note that, chlorpromazine equivalents are a proxy measure to for the comparison of antipsychotic dosage in antipsychotic effectiveness studies. Thus, results emerging from these comparisons should be considered cautiously. Third, treatment adherence measures were collected from selfreport and close observers (family members and social assistants) but not from antipsychotic blood levels. This could have an impact in the accuracy of discontinuation measures due to non-adherence.
On the other hand, this is one of the longest head-to-head antipsychotic effectiveness studies regarding to follow-up (3-year). It was performed on a large (N=376), wellcharacterized and homogeneous sample, as most of patients (97.08%), were antipsychotic naïve prior to their inclusion and comprised some of the most widely used antipsychotic treatments.
Conclusions
Establishing risks and benefits of SGAs treatments and identifying different discontinuation patterns may contribute to make the better treatment selection after a FEP.
In our research, two treatment groups were segregated attending to their performance:
Olanzapine, risperidone and aripiprazole presented clear advantages for the first-line treatment of FEP in terms of effectiveness. In addition, guaranteeing a good adherence to effective antipsychotic treatments is one of the priority challenges in the treatment of FEP individuals to prevent a malignant course of the disease and has proved to be the main reason for discontinuation for the most effective treatments. Finally, balancing most M a n u s c r i p t Table 5 . Concomitant psychiatric medication used during follow-up.
